PTCH1 and skin basal cell carcinoma: In Shh’s absence, PTCH1 impedes Hh pathway activation by inhibiting SMO.[27] Notably, 80% to 90% of sporadic BCC tumors harbor PTCH1 mutations, while approximately 10% exhibit SMO mutations.[28]